Investors Alert: Class Action Filed Against Humacyte, Inc.

Legal Action for Securities Violations

The Schall Law Firm, a national firm specializing in shareholder rights litigation, has announced a class action lawsuit against Humacyte, Inc. (“Humacyte” or “the Company”) HUMA. This lawsuit claims violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 along with Rule 10b-5 enacted by the U.S. Securities and Exchange Commission.

Class Period Details for Affected Investors

Investors who bought Humacyte securities from May 10, 2024, to October 17, 2024, are urged to reach out to the Schall Law Firm before January 17, 2025.

How to Join the Lawsuit

Shareholders who experienced financial losses are invited to participate in the lawsuit. Click here to join.

Contact Information for Legal Rights Inquiry

To discuss your rights at no cost, please contact Brian Schall at the Schall Law Firm, located at 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, or by phone at 310-301-3335. You can also visit the firm’s website at www.schallfirm.com or email bschall@schallfirm.com.

Class Certification Status

Currently, the class has not been certified. Until certification is granted, individuals are not represented by an attorney in this case. Those who decide not to participate will remain absent class members.

Allegations Against Humacyte

The complaint outlines that Humacyte allegedly made false and misleading statements. The Company reportedly did not uphold proper manufacturing practices, including essential microbial testing at its Durham, North Carolina facility. Consequently, the FDA’s review of the Company’s Biologic License Application (BLA) faced delays as Humacyte addressed the manufacturing issues. This situation led to concerns that the FDA might not approve the acellular tissue engineered vessel (“ATEV”) for vascular trauma as expected. These misstatements ultimately caused investor losses when the truth about Humacyte emerged.

Join the Movement to Recover Losses

Affected investors are encouraged to join the case to seek recovery for their losses.

Schall Law Firm’s Commitment

The Schall Law Firm represents investors globally and focuses on securities class action lawsuits and shareholder rights litigation.

Disclaimer: Attorney Advertising

This press release may qualify as Attorney Advertising in certain jurisdictions in accordance with applicable laws and ethical guidelines.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241119136364/en/